Fig. 1

Level of discomfort and inconvenience was self-reported and classified using a 3-point scale: a) mild, did not interfere with daily activity, b) moderate, affected daily activity, and c) severe, prevented daily activity. For redness and induration at/around injection site, the following classification was used: a) mild, reaction at injection of <1 cm in diameter, b) moderate, reaction at injection between 1 and <2 cm in diameter, and c) severe, reaction at injection that is ≥2 cm in diameter. For body temperature, the following classification was used: a) mild, temperature between 37.5 and <39.0 °C, b) moderate, temperature between 39 and <40 °C, and c) severe, temperature ≥40 °C. a In addition to the adverse events shown in the fig. 1b, there were one participant reported a fever onset 25 days after vaccination (resolved in 24 hours of onset), two participants who reported having rash (resolved 10 and 13 days following onset), and two participants with vaccine-unrelated serious adverse events (resolution could not be determined). b From symptom onset